Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

被引：3

作者：

Kelly, Kevin R. ^{[1
]}

Chanan-Khan, Asher ^{[2
]}

Heffner, Leonard T. ^{[3
]}

Somlo, George ^{[4
]}

Siegel, David S. ^{[5
]}

Zimmerman, Todd ^{[6
]}

Karnad, Anand ^{[7
]}

Munshi, Nikhil C. ^{[8
]}

Jagannath, Sundar ^{[9
]}

Greenberg, Allen L. ^{[10
]}

Lonial, Sagar ^{[3
]}

Roy, Vivek ^{[2
]}

Ailawadhi, Sikander ^{[2
]}

Barmaki-Rad, Farima ^{[11
]}

Chavan, Shailesh ^{[12
]}

Patel, Pankaj ^{[12
]}

Wartenberg-Demand, Andrea ^{[11
]}

Haeder, Thomas ^{[11
]}

Anderson, Kenneth C. ^{[13
]}

机构：

[1] Univ So Calif, Los Angeles, CA USA

[2] Mayo Clin, Jacksonville, FL 32224 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[5] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[6] Univ Chicago Med, Chicago, IL USA

[7] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[8] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[9] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[10] Mem Canc Inst, Pembroke Pines, FL USA

[11] Biotest AG, Dreieich, Germany

[12] Biotest Pharmaceut Corp, Boca Raton, FL USA

[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
Kim, Seok Jin
Kang, Danbee
Park, Yong
Mun, Yeung-Chul
Kim, Kihyun
Kim, Jin Seok
Min, Chang-Ki
Cho, Juhee
SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 4969 - 4977
[22] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Moreau, P.
Richardson, P.
Jakubowiak, A.
Jagannath, S.
Raab, M.
Facon, T.
Vij, R.
Reece, D.
White, D.
Benboubker, L.
Zonder, J.
Rossi, J. F.
Tsao, C.
Parli, T.
Kroog, G.
Singhal, A.
Lonial, S.
HAEMATOLOGICA, 2012, 97 : 474 - 474
[23] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Richardson, Paul G.
Xie, Wanling
Jagannath, Sundar
Jakubowiak, Andrzej
Lonial, Sagar
Raje, Noopur S.
Alsina, Melissa
Ghobrial, Irene M.
Schlossman, Robert L.
Munshi, Nikhil C.
Mazumder, Amitabha
Vesole, David H.
Kaufman, Jonathan L.
Colson, Kathleen
McKenney, Mary
Lunde, Laura E.
Feather, John
Maglio, Michelle E.
Warren, Diane
Francis, Dixil
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Mitsiades, Constantine S.
Weller, Edie
Anderson, Kenneth C.
BLOOD, 2014, 123 (10) : 1461 - 1469
[24] Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
San Miguel, Jesus
Mateos, Maria-Victoria
Shah, Jatin J.
Ocio, Enrique M.
Rodriguez-Otero, Paula
Reece, Donna
Munshi, Nikhil C.
Avigan, David
Ge, Yang
Balakumaran, Arun
Marinello, Patricia
Orlowski, Robert Z.
Siegel, David
BLOOD, 2015, 126 (23)
[25] Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kelly, Kevin R.
Ailawadhi, Sikander
Siegel, David S.
Heffner, Leonard T.
Somlo, George
Jagannath, Sundar
Zimmerman, Todd M.
Munshi, Nikhil C.
Madan, Sumit
Chanan-Khan, Asher
Lonial, Sagar
Chandwani, Suraj
Minasyan, Ashot
Ruehle, Markus
Barmaki-Rad, Farima
Abdolzade-Bavil, Afsaneh
Rharbaoui, Faiza
Herrmann-Keiner, Eva
Haeder, Thomas
Wartenberg-Demand, Andrea
Anderson, Kenneth C.
LANCET HAEMATOLOGY, 2021, 8 (11): : E794 - E807
[26] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
Lonial, S.
Vij, R.
Harousseau, J.
Facon, T.
Moreau, P.
Leleu, X.
Westland, C.
Singhal, A. K.
Jagannath, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Lonial, S.
Vij, R.
Harousseau, J. L.
Facon, T.
Moreau, P.
Mazumder, A.
Kaufman, J.
Leleu, X.
Tsao, C.
Fry, J.
Singhal, A.
Jagganath, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
[28] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Richardson, Paul G.
Rocafiguera, Albert Oriol
Beksac, Meral
Liberati, Anna Marina
Galli, Monica
Schjesvold, Fredrik
Lindsay, Jindriska
Weisel, Katja
White, Darell
Facon, Thierry
San-Miguel, Jesus
Sunami, Kazutaka
O'Gorman, Peter
Sonneveld, Pieter
Yu, Xin
Doerr, Thomas
Bensmaine, Amine
Zaki, Mohamed H.
Anderson, Kenneth Carl
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
Firatli-Tuglular, T.
Noyan-Atalay, F.
Eser, A.
Toptas, T.
Pepedil, F.
Kaygusuz-Atagunduz, I.
Adiguzel, C.
HAEMATOLOGICA, 2013, 98 : 614 - 615
[30] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Bahlis, Nizar J.
Sutherland, Heather
White, Darrell
Sebag, Michael
Lentzsch, Suzanne
Kotb, Rami
Venner, Christopher P.
Gasparetto, Cristina
Del Col, Aldo
Neri, Paola
Reece, Donna
Kauffman, Michael
Shacham, Sharon
Unger, T. J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
Chen, Christine
BLOOD, 2018, 132 (24) : 2546 - 2554

← 1 2 3 4 5 →